Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C

Journal of Viral Hepatitis

Volumn 18, Issue 5, 2011, Pages 331-337

  Patel, K ^a,d   Jhaveri, R ^a   George, J ^a   Qiang, G ^a   Kenedi, C ^a   Brown, K ^a   Cates, C ^a   Zekry, A ^b   Tillmann, H L ^a   Elliott, L ^a   Kilaru, R ^a   Albrecht, J ^c   Conrad, A ^c   G McHutchison, J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c National Genetics Institute   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

cholesterol; HMG CoA reductase; lipoprotein; lipoviroparticle; statin

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; ENZYME INHIBITION; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIPID ANALYSIS; MALE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT;

COHORT STUDIES; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINES; RNA, VIRAL; STATISTICS AS TOPIC; SULFONAMIDES;

EID: 79953839424     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01310.x     Document Type: Article

References (30)

1. Dienstag JL, McHutchison JG,. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231-264. (Pubitemid 43049856)
2. Agnello V, Abel G, Elfahal M, et al. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 1999; 96: 12766-12771. (Pubitemid 29513577)
3. Molina S, Castet V, Fournier-Wirth C, et al. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol 2007; 46: 411-419. (Pubitemid 46201721)
4. Petit JM, Minello A, Duvillard L, et al. Cell surface expression of LDL receptor in chronic hepatitis C: correlation with viral load. Am J Physiol Endocrinol Metab 2007; 293: E416-E420. (Pubitemid 47105957)
5. Mas Marques A, Mueller T, Welke J, et al. Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection. Infect Genet Evol 2009; 9: 847-852.
6. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85. (Pubitemid 36775798)
7. Dai CY, Chuang WL, Ho CK, et al. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol 2008; 49: 9-16.
8. Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403-410. (Pubitemid 46185701)
9. Hsu CS, Liu CH, Liu CJ, et al. Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. Antivir Ther 2009; 14: 45-54.
10. Kapadia SB, Chisari FV,. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A 2005; 102: 2561-2566. (Pubitemid 40279416)
11. Ye J, Wang C, Sumpter R Jr, et al. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A 2003; 100: 15865-15870. (Pubitemid 38021081)
12. Ikeda M, Abe K, Yamada M, et al. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 2006; 44: 117-125. (Pubitemid 44049145)
13. Delang L, Paeshuyse J, Vliegen I, et al. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology 2009; 50: 6-16.
14. O'Leary JG, Chan JL, McMahon CM, et al. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology 2007; 45: 895-898. (Pubitemid 46631558)
15. Bader T, Fazili J, Madhoun M, et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 2008; 103: 1383-1389. (Pubitemid 351813920)
16. Huang H, Sun F, Owen DM, et al. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A 2007; 104: 5848-5853. (Pubitemid 47175622)
17. Andre P, Komurian-Pradel F, Deforges S, et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002; 76: 6919-6928. (Pubitemid 41246207)
18. Zeger SL, Liang KY,. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121-130.
19. McKenney JM,. Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am J Health Syst Pharm 2005; 62: 1033-1047.
20. Martin PD, Dane AL, Nwose OM, et al. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharmacol 2002; 42: 1116-1121.
21. McTaggart F,. Comparative pharmacology of rosuvastatin. Atheroscler Suppl 2003; 4: 9-14. (Pubitemid 38234502)
22. White CM,. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002; 42: 963-970. (Pubitemid 34920793)
23. Nezasa K, Higaki K, Matsumura T, et al. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab Dispos 2002; 30: 1158-1163. (Pubitemid 35265820)
24. Nielsen SU, Bassendine MF, Burt AD, et al. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol 2006; 80: 2418-2428. (Pubitemid 43271547)
25. Olsson AG, Pears J, McKellar J, et al. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001; 88: 504-508. (Pubitemid 32778495)
26. Milazzo L, Meroni L, Galazzi M, et al. Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients. J Viral Hepat 2009; 16: 479-484.
27. Voisset C, Callens N, Blanchard E, et al. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem 2005; 280: 7793-7799. (Pubitemid 40349673)
28. Hsu CS, Liu CH, Liu CJ, et al. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection. Am J Gastroenterol 2009; 104: 598-604.
29. Han J, Parsons M, Zhou X, et al. Functional interplay between the macrophage scavenger receptor class B type I and pitavastatin (NK-104). Circulation 2004; 110: 3472-3479. (Pubitemid 39602226)
30. Sezaki H, Suzuki F, Akuta N, et al. An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology 2009; 52: 43-48.